Abstract 6728: Preclinical development of QL325, a novel T cell engager targeting CLEC12A-positive AML
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-6728
Abstract: Despite advancement in targeted therapies, treatment options for patients with acute myeloid leukemia (AML) that provide a tolerable and durable response remain elusive. We have developed a CD3 bispecific antibody, QL325, targeting CLEC12A, a c-type… read more here.
Keywords: ql325 novel; targeting clec12a; cell; development ql325 ... See more keywords